Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024
Cash flows from operating activities:
Net loss	$ (38,718,000)	$ (54,963,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	6,524,000	6,614,000
Loss on disposal of assets	5,000	0
Net (accretion) amortization of (discounts) premiums on investments	(207,000)	(473,000)
Stock-based compensation	6,598,000	9,146,000
Non-cash interest expense related to sale of future royalties	2,277,000	2,045,000
Non-cash revenue related to sale of future royalties	(4,521,000)	(3,596,000)
Change in operating assets and liabilities:
Accounts receivable	(36,955,000)	2,417,000
Unbilled receivable from government contracts	(37,021,000)	(3,085,000)
Prepaid expenses and other assets	1,951,000	(1,170,000)
Prepaid clinical services, long-term	0	(60,116,000)
Accounts payable	46,218,000	940,000
Other accrued liabilities	31,472,000	(625,000)
Net cash used in operating activities	(22,949,000)	(37,419,000)
Cash flows from investing activities:
Purchases of property and equipment	(144,000)	(510,000)
Proceeds from sale of property and equipment	5,000	0
Purchases of investments	(19,218,000)	(48,717,000)
Proceeds from maturities of investments	34,000,000	17,500,000
Net cash provided by (used in) investing activities	14,643,000	(31,727,000)
Cash flows from financing activities:
Proceeds from issuance of common stock upon exercise of stock options	3,000	30,000
Shares acquired to settle employee tax withholding liabilities	(178,000)	(208,000)
Proceeds from issuance of common stock under the employee stock purchase plan	0	312,000
Proceeds from issuance of treasury stock under the employee stock purchase plan	79,000	0
Net cash (used in) provided by financing activities	(43,000)	56,426,000
Net decrease in cash and cash equivalents	(8,349,000)	(12,720,000)
Cash and cash equivalents at beginning of the period	25,229,000	34,755,000
Cash and cash equivalents at end of the period	16,880,000	22,035,000
Supplemental disclosure of non-cash investing and financing activity:
Acquisition of property and equipment included in accounts payable and accrued expenses	0	87,000
June 2024 Offering [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	0	37,545,000
At-the-market Facility [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	53,000	8,802,000
RA Capital Healthcare Fund 2024 [Member]
Cash flows from financing activities:
Net proceeds from issuance of common stock	0	9,945,000
Government Contract [Member]
Change in operating assets and liabilities:
Deferred revenue	$ (572,000)	$ 65,447,000